AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
By Neel Chudgar, MD
The surgery-versus-radiation debate in stage III NSCLC is increasingly the wrong framing; the better approach is starting with the best available systemic therapy
Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
By Neel Chudgar, MD
The surgery-versus-radiation debate in stage III NSCLC is increasingly the wrong framing; the better approach is starting with the best available systemic therapy
Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
By Neel Chudgar, MD
The surgery-versus-radiation debate in stage III NSCLC is increasingly the wrong framing; the better approach is starting with the best available systemic therapy
Combining Immunotherapy With Local Treatment Advances Liver Cancer Care, While a Provocative New Question Emerges About Diabetes Drugs
By Ursa Brown-Glaberman, MD
For more than two decades, transarterial chemoembolization (TACE) has been the standard of care for unresectable hepatocellular carcinoma (HCC) eligible for embolization, typically producing a median progression-free survival of eight to ten months.
Combining Immunotherapy With Local Treatment Advances Liver Cancer Care, While a Provocative New Question Emerges About Diabetes Drugs
By Ursa Brown-Glaberman, MD
For more than two decades, transarterial chemoembolization (TACE) has been the standard of care for unresectable hepatocellular carcinoma (HCC) eligible for embolization, typically producing a median progression-free survival of eight to ten months.
Combining Immunotherapy With Local Treatment Advances Liver Cancer Care, While a Provocative New Question Emerges About Diabetes Drugs
By Ursa Brown-Glaberman, MD
For more than two decades, transarterial chemoembolization (TACE) has been the standard of care for unresectable hepatocellular carcinoma (HCC) eligible for embolization, typically producing a median progression-free survival of eight to ten months.
Targeting Endocrine Resistance: New Sequencing Strategies in Metastatic Breast Cancer
By Jaspreet Kaur, MD
Hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed on a CDK4/6 inhibitor now has multiple biomarker-guided options
Targeting Endocrine Resistance: New Sequencing Strategies in Metastatic Breast Cancer
By Jaspreet Kaur, MD
Hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed on a CDK4/6 inhibitor now has multiple biomarker-guided options
Targeting Endocrine Resistance: New Sequencing Strategies in Metastatic Breast Cancer
By Jaspreet Kaur, MD
Hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed on a CDK4/6 inhibitor now has multiple biomarker-guided options
Advances in the Management of Lung Cancer in 2025 and 2026
By Siddhartha Devarakonda, MD; Carly Irwin, RN, BScN
Recent approvals in NSCLC and SCLC have advanced targeted therapies, immunotherapies, and antibody-drug conjugates across both diseases.
Advances in the Management of Lung Cancer in 2025 and 2026
By Siddhartha Devarakonda, MD; Carly Irwin, RN, BScN
Recent approvals in NSCLC and SCLC have advanced targeted therapies, immunotherapies, and antibody-drug conjugates across both diseases.
Advances in the Management of Lung Cancer in 2025 and 2026
By Siddhartha Devarakonda, MD; Carly Irwin, RN, BScN
Recent approvals in NSCLC and SCLC have advanced targeted therapies, immunotherapies, and antibody-drug conjugates across both diseases.
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care
By Joe Schroers-Martin, MD
Bruton's tyrosine kinase (BTK) inhibitor combinations now anchor frontline mantle cell lymphoma treatment across age and fitness categories, including chemotherapy-free regimens for older patients and TP53-mutated disease.
Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care
By Joe Schroers-Martin, MD
Bruton's tyrosine kinase (BTK) inhibitor combinations now anchor frontline mantle cell lymphoma treatment across age and fitness categories, including chemotherapy-free regimens for older patients and TP53-mutated disease.
Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care
By Joe Schroers-Martin, MD
Bruton's tyrosine kinase (BTK) inhibitor combinations now anchor frontline mantle cell lymphoma treatment across age and fitness categories, including chemotherapy-free regimens for older patients and TP53-mutated disease.